Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignant melanoma

L E Spitler

    The Journal of Investigative Dermatology
    |September 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Advances in understanding malignant melanoma pathology enable new immunotherapeutic studies. While specific immune responses to melanoma antigens are debated, novel agents like BCG offer potential therapeutic improvements for patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma.

    Critical reviews in oncology/hematology·2001
    Same author

    Adjuvant therapy of melanoma: at what cost?

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
    Same author

    Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer.

    The Prostate·2001
    Same author

    Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma.

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2000
    Same author

    Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery.

    Journal of pharmaceutical sciences·1999
    Same journal

    Introducing lesion-level metrics for melanocytic neoplasm clustering: Practical tools with potential applications in clinical practice.

    The Journal of investigative dermatology·2026
    Same journal

    Reducing plastic waste in skin-model research: Sustainable packaging as a practical first step.

    The Journal of investigative dermatology·2026
    Same journal

    Modern serum proteomics in precision medicine: Toward disease stratification and predictive, proactive treatment strategies.

    The Journal of investigative dermatology·2026
    Same journal

    An Integrated Skin Cell Atlas Decodes the Pilosebaceous Unit.

    The Journal of investigative dermatology·2026
    Same journal

    Residual CSB activity explains mild UV-sensitive syndrome phenotype caused by CSB mutations.

    The Journal of investigative dermatology·2026
    Same journal

    Charting a new melanoma risk factor: Satellite Naevus Prevalence in High-Risk and Population-Based Cohorts.

    The Journal of investigative dermatology·2026
    See all related articles

    Area of Science:

    • Immunology
    • Oncology
    • Dermatology

    Background:

    • Malignant melanoma understanding has advanced, enabling rational immunotherapeutic study design.
    • Immunologic studies suggest specific immune responses to melanoma-associated antigens, but specificity remains unresolved.
    • Current research explores novel immunotherapeutic agents for melanoma treatment.

    Purpose of the Study:

    • To review recent advances in malignant melanoma pathology and prognosis.
    • To evaluate the evidence for specific immune responses in melanoma patients.
    • To discuss the potential of new immunotherapeutic agents in improving melanoma therapy.

    Main Methods:

    • Literature review of recent immunologic and therapeutic studies in malignant melanoma.
    • Analysis of studies investigating melanoma-associated antigens and patient immune responses.

    Related Experiment Videos

  • Examination of novel immunotherapeutic agents such as BCG, TF, and levamisole.

    • Main Results:

    • Understanding of melanoma pathology and prognosis has improved.
    • Evidence for specific immune responses to melanoma-associated antigens is inconclusive.
    • New agents like BCG, TF, and levamisole show promise for melanoma therapy.

    Conclusions:

    • Rationally designed immunotherapeutic studies are now feasible for malignant melanoma.
    • The specificity of immune responses to melanoma antigens requires further investigation.
    • Novel immunotherapeutic agents present a potential avenue for enhanced melanoma treatment.